Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, CRISPR Therapeutics AG (NASDAQ: CRSP) closed at $34.03 down -8.00% from its previous closing price of $36.99. In other words, the price has decreased by -$8.00 from its previous closing price. On the day, 3.96 million shares were traded. CRSP stock price reached its highest trading level at $35.67 during the session, while it also had its lowest trading level at $32.96.
Ratios:
For a deeper understanding of CRISPR Therapeutics AG’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 22.07 and its Current Ratio is at 22.07. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on February 14, 2025, Upgraded its rating to Outperform and sets its target price to $99 from $60 previously.
On February 12, 2025, TD Cowen Upgraded its rating to Hold which previously was Sell but kept the price unchanged to $35.
On February 03, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $65.H.C. Wainwright initiated its Buy rating on February 03, 2025, with a $65 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 21 ’25 when Kulkarni Samarth sold 10,031 shares for $41.23 per share. The transaction valued at 413,578 led to the insider holds 195,085 shares of the business.
Bruno Julianne sold 1,714 shares of CRSP for $70,668 on Mar 21 ’25. The Chief Operating Officer now owns 10,544 shares after completing the transaction at $41.23 per share. On Mar 21 ’25, another insider, Prasad Raju, who serves as the Chief Financial Officer of the company, sold 2,197 shares for $41.23 each. As a result, the insider received 90,582 and left with 16,767 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 3172796928 and an Enterprise Value of 1238772352. For the stock, the TTM Price-to-Sale (P/S) ratio is 78.23 while its Price-to-Book (P/B) ratio in mrq is 1.51. Its current Enterprise Value per Revenue stands at 33.199 whereas that against EBITDA is -2.769.
Stock Price History:
The Beta on a monthly basis for CRSP is 1.81, which has changed by -0.47670305 over the last 52 weeks, in comparison to a change of 0.077997446 over the same period for the S&P500. Over the past 52 weeks, CRSP has reached a high of $68.39, while it has fallen to a 52-week low of $36.52. The 50-Day Moving Average of the stock is -20.46%, while the 200-Day Moving Average is calculated to be -28.54%.
Shares Statistics:
For the past three months, CRSP has traded an average of 2.10M shares per day and 1846900 over the past ten days. A total of 85.74M shares are outstanding, with a floating share count of 82.06M. Insiders hold about 4.33% of the company’s shares, while institutions hold 69.35% stake in the company. Shares short for CRSP as of 1741910400 were 20307836 with a Short Ratio of 9.66, compared to 1739491200 on 20407467. Therefore, it implies a Short% of Shares Outstanding of 20307836 and a Short% of Float of 26.82.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
